The Swiss Competition Commission issues a prohibition order and fined three producers of medicine (treatment of erectile dysfunction) for publishing recommended prices leading to RPM (Pfizer / Eli Lilly / Bayer)

KEYWORDS
Reference

Swiss Competition Commission, Pfizer / Eli Lilly / Bayer, Decision No. 22-0326, 2 November 2009 (French)

Description of the impugned case Three pharmaceutical manufacturers issued recommended retail prices (RRP) which were integrated into a widely used IT-Database or/and communicated to all resellers (e.g. pharmacies). 63% of all resellers adopted a pricing policy according to the price recommendation. There were

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Authors

Quotation

Patrick Krauskopf, Orly Ben-Attia, The Swiss Competition Commission issues a prohibition order and fined three producers of medicine (treatment of erectile dysfunction) for publishing recommended prices leading to RPM (Pfizer / Eli Lilly / Bayer), 2 November 2009, e-Competitions November 2009, Art. N° 32507

Visites 1882

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues